


NLM Citation: Leung K. Hyperpolarized [1-¹³C]dehydroascorbic acid. 2011 Sep 15 [Updated 2011 Dec 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Hyperpolarized [1-13C]dehydroascorbic acid

[1-¹³C]DHA

Kam Leung, PhD^{図1}

Created: September 15, 2011; Updated: December 15, 2011.

Target Category: Method of detection: Source of signal / contrast:	[1- ¹³ C]dehydroascorbic acid [1- ¹³ C]DHA Compound Thoredoxin reductases Enzyme Magnetic resonance imaging (MRI)/magnetic resonance spectroscopy (MRS) Hyperpolarized ¹³ C	0 0 0 0 0
Activation:	No	
Studies:	 In vitro Rodents	Click on the above structure for additional information in PubChem

Background

[PubMed]

Magnetic resonance spectroscopy (MRS) has been noninvasively used to detect small molecules in tissues *in vivo* (1-4). Proton (1 H) and carbon-13 (13 C) are the most frequently investigated MRS applications (5-7). One technique has been often used to enhance 13 C nuclear spins with dynamic nuclear polarization (DNP), which dramatically increases sensitivities in MRS spectra of 13 C-labeled substrates in solutions and tissues (2, 3, 8). DNP transfers high electron-spin polarization to nuclear spins *via* microwave irradiation. The 13 C MRS signals from tissues are near background levels, whereas regions with hyperpolarized 13 C-labeled substrates provide strong signals. Thus, hyperpolarized 13 C-labeled substrates can provide >10,000-fold enhancement of the 13 C MRS signals from the substrate and its subsequent metabolites. 13 C-Labeled substrates must exhibit long spinlattice relaxation time (T_1) values, be rapidly metabolized, and produce an observable change in the chemical

Author Affiliation: 1 National Center for Biotechnology Information, NLM, NIH; Email: micad@ncbi.nlm.nih.gov.

shift (δ) value between the substrate and its metabolite(s). ¹³C-Labeled substrates, such as [1-¹³C]pyruvate, [2-1³C]fructose, [¹³C]bicarbonate, α -keto[1-¹³C]isocaproate, and [1,4-¹³C₂]fumarate have been studied using the DNP technique in tumors in preclinical studies to measure changes in metabolism *in vivo* through glycolysis, citric acid cycle, amino acid metabolism and fatty acid synthesis (1-3).

Vitamin C (ascorbic acid, AA) is reversibly oxidized to DHA, which is a substrate of glucose transporters GLUT1 and GLUT3 (9). Epithelial cells of the intestine, liver, and kidney transport AA directly through sodium-dependent transporters, whereas most normal tissues acquire AA through transport of DHA (10). Intracellular DHA is then converted to AA through reaction with glutathione (GSH) or GSH-dependent enzymes and through NADPH-dependent thioredoxin reductases (11). On the other hand, tumor cells have been found to lack the capacity to transport AA and to exhibit upregulation of the GSH and thioredoxin antioxidant systems, reflecting high oxidative stress in tumor cells (10). High oxidative stress has also been implicated in neurodegenerative and cardiovascular conditions (12). Bohndiek et al. (13) generated a hyperpolarized small molecule, [1-¹³C]dehydroascorbic acid ([1-¹³C]DHA), as an imaging agent of ¹³C MRS for evaluation of intracellular reduction/oxidation (redox) status in tumors and other pathological conditions. [1-¹³C]DHA has been evaluated as an intracellular redox probe using tumor cells *in vitro* and *in vivo*. Keshari et al. (14) have performed MRS imaging of redox status in normal organs and prostate tumor in mice using hyperpolarized [1-¹³C]DHA.

Related Resource Links:

- Chapters in MICAD (Hyperpolarized ¹³C)
- Gene information in NCBI (Thioredoxin reductase 1, thioredoxin reductase 2, GLUT1, GLUT3).
- Articles in Online Mendelian Inheritance in Man (OMIM) (Thioredoxin reductase 1, thioredoxin reductase 2, GLUT1, GLUT3)

Synthesis

[PubMed]

[1-¹³C]DHA was prepared by charcoal oxidation of commercially available [1-¹³C]AA. [1-¹³C]AA 1 (2.9 mmol) was dissolved in 15 mL methanol, and then highly purified activated charcoal Norit (0.75 g) was added as a catalyst (13). The mixture was stirred vigorously for 90 minutes at room temperature, with oxygen bubbled through at 0.2 L/minute. Charcoal was removed from the product with filtration. The final product, [1-¹³C]DHA, was then lyophilized to give a yield of 70% with >99% chemical purity. [1-¹³C]DHA (8.2 ± 1.1%, n = 8) exhibited a significantly higher degree of polarization (P < 0.05) than [1-¹³C]AA (5.1 ± 0.6%, n = 6) at pH 7 at 8 s after dissolution in phosphate-buffered saline (PBS) measured at 9.4 T. The δ values for [1-¹³C]AA and [1-¹³C]DHA were 179 ppm and 175 ppm, respectively. The T_1 values for [1-¹³C]AA and [1-¹³C]DHA were 15.9 ± 0.7 s and 20.5 ± 0.9 s, respectively.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Bohndiek et al. (13) analyzed the conversion of $[1^{-13}C]DHA$ to $[1^{-13}C]AA$ in PBS containing 1, 5, 10, 25, and 50 mM GSH. ¹³C MRS spectra were acquired at 9.4 T. The $[1^{-13}C]AA$ signal (179 ppm) reached maximal intensity within 7–16 s. Reduction of $[1^{-13}C]DHA$ to $[1^{-13}C]AA$ was observed in RPMI medium, which contains 3.3 nM GSH and other factors. The rate of conversion observed in RPMI medium and EL4 mouse lymphoma cell suspension $(1 \times 10^8 \text{ cells in 2 mL})$ in RPMI medium were 99 ± 6 nmol/s (n = 2) and 223 ± 18 nmol/s (n = 3), respectively. On the other hand, no oxidation of $[1^{-13}C]AA$ to $[1^{-13}C]DHA$ was observed in either RPMI medium alone or in EL4 cell suspension in RPMI medium within 60 s.

[1-¹³C]DHA

Animal Studies

Rodents

[PubMed]

Bohndiek et al. (13) performed *in vivo* MRS studies in female C57BL/6 mice (number of mice not reported) bearing subcutaneous EL4 tumors. Hyperpolarized $[1^{-13}C]AA$ or $[1^{-13}C]DHA$ (6 mmol/mouse) was injected *via* tail vein catheter over a period of ~6 s. ^{13}C MRS spectra were acquired at 9.4 T. After injection of $[1^{-13}C]DHA$, the signals from $[1^{-13}C]AA$ and $[1^{-13}C]DHA$ were seen at 179 ppm and 175 ppm in the tumors, respectively. The apparent rate constant for the conversion of $[1^{-13}C]DHA$ to $[1^{-13}C]AA$ was 0.020 ± 0.004 s $^{-1}$. The ratio of the peak integrals of $[1^{-13}C]AA$ to $[1^{-13}C]DHA$ was 0.35 ± 0.08 with an average signal/noise ratio of 67 \pm 20. The EL4 tumor concentration of GSH was determined to be 1,180 nmol/g. The calculated spontaneous reaction rate constant of $[1^{-13}C]DHA$ to $[1^{-13}C]AA$ with GSH was 0.0004 s $^{-1}$ and would produce a maximum relative signal of only 0.013 for $[1^{-13}C]AA$ in the tumors. These data suggest that an enzymatic reaction is required to account for the high rate and level of $[1^{-13}C]AA$ produced from $[1^{-13}C]DHA$ observed in the tumors. On the other hand, no observable $[1^{-13}C]DHA$ signal was detected in the tumors after injection of $[1^{-13}C]AA$.

Keshari et al. (14) performed *in vivo* MRS imaging (3 T) in normal mice (n = 5) and in transgenic mice (n = 4) with adenocarcinoma of the mouse prostate (TRAMP) model after injection of 17.5 mmol of hyperpolarized [1-¹³C]DHA. T2-weighted images were obtained for 25 s at the start of [1-¹³C]DHA injection. The conversion of [1-¹³C]DHA to [1-¹³C]AA was measured as a ratio of [AA]/[AA+DHA]. In normal mice, the conversions were rapid in the liver (0.41 ± 0.03) and kidney (0.25 ± 0.03), and were significantly different (P < 0.01). These ratios were similar in TRAMP mice. In tumors of TRAMP mice, the ratio was 0.23 ± 0.03 and significantly higher than that in the normal prostate (0.06 ± 0.03, P < 0.02). Hyperpolarized ¹³C MRS imaging data acquired from rat brains (n = 3) demonstrated an even faster conversion (0.51 ± 0.10) with [1-¹³C]AA localized to the brain and [1-¹³C]DHA localized to the surrounding muscle tissue. In summary, the conversions of [1-¹³C]DHA to [1-¹³C]AA were rapid in the brain, liver, kidney, and TRAMP tumor. The conversions were slow in the normal prostate and muscle.

Other Non-Primate Mammals

[PubMed]

No references are currently available.

Non-Human Primates

[PubMed]

No references are currently available.

Human Studies

[PubMed]

No references are currently available.

References

1. Gallagher F.A., Kettunen M.I., Hu D.E., Jensen P.R., Zandt R.I., Karlsson M., Gisselsson A., Nelson S.K., Witney T.H., Bohndiek S.E., Hansson G., Peitersen T., Lerche M.H., Brindle K.M. *Production of*

- hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. . Proc Natl Acad Sci U S A. 2009;106(47):19801–6. PubMed PMID: 19903889.
- 2. Kurhanewicz J., Bok R., Nelson S.J., Vigneron D.B. *Current and potential applications of clinical 13C MR spectroscopy.* . J Nucl Med. 2008;49(3):341–4. PubMed PMID: 18322118.
- 3. Mansson S., Johansson E., Magnusson P., Chai C.M., Hansson G., Petersson J.S., Stahlberg F., Golman K. *13C imaging-a new diagnostic platform.* . Eur Radiol. 2006;16(1):57–67. PubMed PMID: 16402256.
- 4. Gallagher F.A., Bohndiek S.E., Kettunen M.I., Lewis D.Y., Soloviev D., Brindle K.M. *Hyperpolarized 13C MRI and PET: In Vivo Tumor Biochemistry.* . J Nucl Med. 2011;52(9):1333–6. PubMed PMID: 21849405.
- 5. Chen A.P., Tropp J., Hurd R.E., Van Criekinge M., Carvajal L.G., Xu D., Kurhanewicz J., Vigneron D.B. *In vivo hyperpolarized 13C MR spectroscopic imaging with 1H decoupling*. J Magn Reson. 2009;197(1):100–6. PubMed PMID: 19112035.
- 6. Ardenkjaer-Larsen J.H., Fridlund B., Gram A., Hansson G., Hansson L., Lerche M.H., Servin R., Thaning M., Golman K. *Increase in signal-to-noise ratio of* > 10,000 times in liquid-state NMR. . Proc Natl Acad Sci U S A. 2003;100(18):10158–63. PubMed PMID: 12930897.
- 7. Golman K., Ardenkjaer-Larsen J.H., Petersson J.S., Mansson S., Leunbach I. *Molecular imaging with endogenous substances*. Proc Natl Acad Sci U S A. 2003;100(18):10435–9. PubMed PMID: 12930896.
- 8. Golman K., Olsson L.E., Axelsson O., Mansson S., Karlsson M., Petersson J.S. *Molecular imaging using hyperpolarized 13C.* . Br J Radiol. 2003;76(Spec No 2):S118–27. PubMed PMID: 15572334.
- 9. Rumsey S.C., Kwon O., Xu G.W., Burant C.F., Simpson I., Levine M. *Glucose transporter isoforms GLUT1* and GLUT3 transport dehydroascorbic acid. J Biol Chem. 1997;272(30):18982–9. PubMed PMID: 9228080.
- 10. Corti A., Casini A.F., Pompella A. *Cellular pathways for transport and efflux of ascorbate and dehydroascorbate*. Arch Biochem Biophys. 2010;500(2):107–15. PubMed PMID: 20494648.
- 11. Linster C.L., Van Schaftingen E. *Vitamin C. Biosynthesis, recycling and degradation in mammals.* . FEBS J. 2007;274(1):1–22. PubMed PMID: 17222174.
- 12. Ballatori N., Krance S.M., Notenboom S., Shi S., Tieu K., Hammond C.L. *Glutathione dysregulation and the etiology and progression of human diseases*. Biol Chem. 2009;390(3):191–214. PubMed PMID: 19166318.
- 13. Bohndiek S.E., Kettunen M.I., Hu D.E., Kennedy B.W., Boren J., Gallagher F.A., Brindle K.M. *Hyperpolarized [1-13C]-ascorbic and dehydroascorbic acid: vitamin C as a probe for imaging redox status in vivo.* . J Am Chem Soc. 2011;133(30):11795–801. PubMed PMID: 21692446.
- 14. Keshari K.R., Kurhanewicz J., Bok R., Larson P.E., Vigneron D.B., Wilson D.M. *Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging.* Proc Natl Acad Sci U S A. 2011;108(46):18606–11. PubMed PMID: 22042839.